Executive dysfunction predicts nonresponse to fluoxetine in major depression.

J Affect Disord

Department of Psychiatry and Biobehavioral Sciences, UCLA NPI 37-439 School of Medicine, 760 Westwood Plaza, Los Angeles, CA 90024, USA.

Published: October 2000

Background: Functional brain imaging studies of major depression have consistently revealed hypometabolism or hypoperfusion in specific regions of the prefrontal cortex and basal ganglia. Studies of cognitive functioning in major depression have suggested that some but not all subjects exhibit cognitive deficits that are consistent with frontal-subcortical dysfunction, although the reasons for this heterogeneity are unclear. In this study, we explored this heterogeneity among depressed subjects by examining the relationship between cognitive functioning and treatment outcome.

Method: Subjects with major depression were administered a complete neuropsychological test battery prior to treatment with fluoxetine.

Results: There were no significant differences between responders and nonresponders to fluoxetine in terms of age, educational achievement, number of past episodes of depression, and estimated premorbid IQ. However, nonresponders performed significantly worse than responders on several pretreatment measures of executive functioning, after controlling for baseline group differences in depression severity.

Limitations: The results are based on a small sample of primarily female subjects, resulting in low statistical power and less generalizability to samples of male subjects with depression.

Conclusions: The findings suggest that subtle prefrontal dysfunction in subjects with major depression may be predictive of poor response with particular medications. Assessment of the executive functions may play a particular role in pretreatment identification of subjects likely to respond to specific medications.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0165-0327(99)00157-3DOI Listing

Publication Analysis

Top Keywords

major depression
20
cognitive functioning
8
subjects major
8
depression
7
subjects
7
major
5
executive dysfunction
4
dysfunction predicts
4
predicts nonresponse
4
nonresponse fluoxetine
4

Similar Publications

Is there a mental health diagnostic crisis in primary care? Current research practices in global mental health cannot answer that question.

Epidemiol Psychiatr Sci

January 2025

Health Service and Population Research Department, Institute of Psychiatry, Psychology and Neuroscience, Center for Global Mental Health, King's College London, London, UK.

In low- and middle-income countries, fewer than 1 in 10 people with mental health conditions are estimated to be accurately diagnosed in primary care. This is despite more than 90 countries providing mental health training for primary healthcare workers in the past two decades. The lack of accurate diagnoses is a major bottleneck to reducing the global mental health treatment gap.

View Article and Find Full Text PDF

Effects of psilocybin on mouse brain microstructure.

AJNR Am J Neuroradiol

January 2025

From the Department of Radiology (P.C.F., A.P.S., J.J.Y.).

Background And Purpose: There is surging interest in the therapeutic potential of psychedelic compounds like psilocybin in the treatment of psychiatric illnesses like major depressive disorder (MDD). Recent studies point to the rapid antidepressant effect of psilocybin; however, the biological mechanisms underlying these differences remain unknown. This study determines the feasibility of using diffusion MRI to characterize and define the potential spatiotemporal microstructural differences in the brain following psilocybin treatment in C57BL/6J male mice.

View Article and Find Full Text PDF

Mental Well-being in Menopause.

Obstet Gynecol Clin North Am

March 2025

Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO 80045, USA. Electronic address:

The hormonal changes that accompany the transition to menopause are disruptive to most women, and for some, mental health maybe adversely affected. Depressive symptoms and major depression are the best-studied conditions in association with menopause, but anxiety, executive function, and comorbid pre-existing psychiatric conditions all influence the symptomatology that women will experience during this phase of their lives. The epidemiology, diagnosis, and evidence-based treatment guidelines for perimenopausal patients are discussed.

View Article and Find Full Text PDF

This is a review of the existing literature and guidelines for the screening, management, and follow-up of perinatal mood and anxiety disorders, with a focus on major depressive disorder and generalized anxiety disorder.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!